NOT FOR DISTRIBUTION
Header cover image

Market Cap

UK£102.0m

Last Updated

2021/05/07 19:35 UTC

Data Sources

Company Financials +

Executive Summary

Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and internationally. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Yourgene Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: YGEN is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: YGEN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.


Market Performance


7 Day Return

0.8%

YGEN

1.6%

GB Medical Equipment

2.1%

GB Market


1 Year Return

-23.7%

YGEN

2.9%

GB Medical Equipment

26.6%

GB Market

Return vs Industry: YGEN underperformed the UK Medical Equipment industry which returned 2.2% over the past year.

Return vs Market: YGEN underperformed the UK Market which returned 25.5% over the past year.


Shareholder returns

YGENIndustryMarket
7 Day0.8%1.6%2.1%
30 Day-2.7%13.4%3.6%
90 Day6.5%5.2%9.6%
1 Year-23.7%-23.7%4.8%2.9%32.1%26.6%
3 Year78.6%78.6%25.4%18.2%12.8%-0.2%
5 Year54.7%54.7%47.7%35.5%51.8%23.0%

Long-Term Price Volatility Vs. Market

How volatile is Yourgene Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Yourgene Health undervalued compared to its fair value and its price relative to the market?

2.18x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: YGEN (£0.14) is trading above our estimate of fair value (£0.13)

Significantly Below Fair Value: YGEN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: YGEN is unprofitable, so we can't compare its PE Ratio to the GB Medical Equipment industry average.

PE vs Market: YGEN is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate YGEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: YGEN is good value based on its PB Ratio (2.2x) compared to the GB Medical Equipment industry average (3.7x).


Future Growth

How is Yourgene Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

122.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: YGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: YGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: YGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: YGEN's revenue (21.2% per year) is forecast to grow faster than the UK market (5.3% per year).

High Growth Revenue: YGEN's revenue (21.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if YGEN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Yourgene Health performed over the past 5 years?

38.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: YGEN is currently unprofitable.

Growing Profit Margin: YGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: YGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 38.8% per year.

Accelerating Growth: Unable to compare YGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: YGEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (13.8%).


Return on Equity

High ROE: YGEN has a negative Return on Equity (-8.48%), as it is currently unprofitable.


Financial Health

How is Yourgene Health's financial position?


Financial Position Analysis

Short Term Liabilities: YGEN's short term assets (£20.2M) exceed its short term liabilities (£9.1M).

Long Term Liabilities: YGEN's short term assets (£20.2M) exceed its long term liabilities (£7.3M).


Debt to Equity History and Analysis

Debt Level: YGEN's debt to equity ratio (0.7%) is considered satisfactory.

Reducing Debt: YGEN's debt to equity ratio has increased from 0.2% to 0.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: YGEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if YGEN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Yourgene Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate YGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate YGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if YGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if YGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of YGEN's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Lyn Rees (46 yo)

2.83yrs

Tenure

UK£219,739

Compensation

Mr. Lyn Dafydd Rees serves as Non-Executive Director at MyHealthChecked Plc (formerly known as Concepta PLC) since November 2019. Mr. Rees serves as Chief Executive Officer at Yourgene Health PLC and holds...


CEO Compensation Analysis

Compensation vs Market: Lyn's total compensation ($USD304.99K) is about average for companies of similar size in the UK market ($USD338.34K).

Compensation vs Earnings: Lyn's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: YGEN's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: YGEN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: YGEN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.3%.


Top Shareholders

Company Information

Yourgene Health Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Yourgene Health Plc
  • Ticker: YGEN
  • Exchange: AIM
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£102.046m
  • Shares outstanding: 723.06m
  • Website: https://www.yourgene-health.com

Number of Employees


Location

  • Yourgene Health Plc
  • Citylabs 1.0
  • Nelson Street
  • Manchester
  • Greater Manchester
  • M13 9NQ
  • United Kingdom

Listings


Biography

Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and inter...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/07 19:35
End of Day Share Price2021/05/07 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.